Review Timeline | CrossMark Policy | ClinMed Features
logo
Clinical Archives of
Bone and Joint Diseases ISSN: 2643-4091

Citation

Candelas G, Villaverde V, Dïaz P, Guerra M, Naranjo A (2019) Risk of Osteonecrosis of the Jaw in Patients with Postmenopausal Osteoporosis: A Systematic Literature Review. Clin Arch Bone Joint Dis 2:010. doi.org/10.23937/2643-4091/1710010

Copyright

© 2019 Deinlein DA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

SYSTEMATIC REVIEW | OPEN ACCESS DOI: 10.23937/2643-4091/1710010

Risk of Osteonecrosis of the Jaw in Patients with Postmenopausal Osteoporosis: A Systematic Literature Review

Gloria Candelas1*, Virginia Villaverde2, Petra Dïaz3, Mercedes Guerra3 and Antonio Naranjo4

1Rheumatology Unit, Hospital Clínico San Carlos, Madrid, Spain

2Rheumatology Unit, Hospital Universitario de Móstoles, Spain

3Investigation Unit, Spanish Society of Rheumatology, Spain

4Rheumatology Unit, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain

Abstract

Objective

To systematically review the literature available on the use of Denosumab (Dmab) in osteoporosis and the risk of ONJ.

Methods

The studies retrieved by the above strategies were included if they met the following pre-established criteria. The patients studied had to be diagnosed of osteoporosis (all ages, both sexes), and they had to be taking Dmab. We measured the likelihood of having osteonecrosis of the jaw. We included in the search for systematic reviews randomised clinical trials (RCT) and cohort studies. We excluded articles on cancer or other disease other than osteoporosis, animal and basic science studies. There was no limitation with regard to the number of patients included in the studies. The bibliographic databases screened were Medline and Embase and the Cochrane. The searches were conducted with language restriction (English, French and Spanish).

Results

We found 10 articles that were studied in detail because by title or abstract they seemed to be related to the study, or because they had no abstract to review. Finally, 2 studies were included (one of them by indirect search) (Table 1). One of the study included was case series and another was systematic review of cases and series of cases and their data retrieved. The quality level of the two articles was low. Related to the studies population, all patients had osteoporosis, mostly were women with mean ages around 50-78 years. All patients were treated with subcutaneous denosumab every 6 months.

Table 1: Main characteristics of the included studies. View Table 1

In these two studies, the incidence of ONJ was very low. Some systemic factors such as previous treatment with BPs or dental extractions are associated with the development of osteonecrosis of the jaws in patients treated with Dmab. Stage 1 of ONJ was the most common and conservative treatment was used with the healing of the lesions.

Conclusions

There are not enough studies that have evaluated the role of Dmab in the development of osteonecrosis (ONJ) of the jaws. Some systemic factors that have been associated with the development of ONJ are described in patients treated with Dmab, such as previous treatment with bisphosphonates or tooth extractions.